RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+4.51%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$791M
AUM Growth
+$791M
(-9.1%)
Cap. Flow
-$75.2M
Cap. Flow
% of AUM
-9.51%
Top 10 Holdings %
Top 10 Hldgs %
32.88%
Holding
105
New
11
Increased
29
Reduced
37
Closed
15
Top Buys
| 1 |
Danaher
DHR
|
$15.7M |
| 2 |
Eli Lilly
LLY
|
$12.6M |
| 3 |
Encompass Health
EHC
|
$12.1M |
| 4 |
Cardinal Health
CAH
|
$9.24M |
| 5 |
Neurocrine Biosciences
NBIX
|
$7.47M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$19.8M |
| 2 |
Oscar Health
OSCR
|
$15.2M |
| 3 |
Procept Biorobotics
PRCT
|
$14.9M |
| 4 |
UnitedHealth
UNH
|
$14.7M |
| 5 |
McKesson
MCK
|
$14.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Immunovant
IMVT
$2.56B
| – | – | -25,924 | Closed | -$443K |
|
102
Medpace
MEDP
$13.4B
| – | – | -3,800 | Closed | -$1.16M |
|
103
Merck
MRK
$210B
| – | – | -33,000 | Closed | -$2.96M |
|
104
Vir Biotechnology
VIR
$686M
| – | – | -200,000 | Closed | -$1.3M |
|
105
Zimmer Biomet
ZBH
$21B
| – | – | -87,250 | Closed | -$9.87M |
|